CLL is the most common form of leukemia in Western countries, but it behaves very differently from patient to patient. Some people live for decades without needing therapy, while others progress more rapidly and require treatment soon after diagnosis. Because early-stage CLL is often asymptomatic and immediate therapy has not been shown to change the disease’s natural history, physicians commonly monitor patients through regular examinations and blood tests. This strategy, known as active surveillance or watch-and-wait, avoids exposing people to treatment-related risks before treatment is necessary. It also creates a distinctive scientific challenge: there are few established interventions that can be tested during this period to delay progression. Supportive care is generally focused on monitoring, managing infections and other complications, and maintaining overall health. The new study therefore addresses a question with potentially broad appeal: whether an inexpensive, widely available nutrient could be associated with a longer period before chemotherapy, targeted therapy or another CLL-directed treatment becomes necessary.

The investigators examined electronic health records from Clalit Health Services covering the period from January 1, 2000, through December 31, 2022. They initially identified 5,505 people who met diagnostic criteria for CLL and had been managed with watch-and-wait for at least three months. Nine patients were not included in the final analysis, leaving 5,496 participants. The median age at diagnosis was 72.2 years, and 55.6 percent were male. Patients were followed from diagnosis until they began their first CLL-directed treatment or were censored from the analysis. Vitamin D exposure was defined relatively stringently: a patient had to receive vitamin D supplementation, a vitamin D analog, or both for at least six months during the watch-and-wait period. In total, 1,862 patients—34 percent of the final cohort—met that definition, while 3,634 did not. The median follow-up from diagnosis to treatment or death was 46 months, although the reported interquartile range extended from 19 to 89 months.

The study’s primary outcome was treatment-free survival, or TFS, a composite measure that counted either the start of CLL therapy or death. The researchers also assessed time to first treatment, known as TTFT, while treating death as a censoring event in that analysis. Because vitamin D use was not assigned randomly, the investigators used several statistical techniques to reduce the influence of differences between patients. A multivariable time-dependent Cox proportional hazards model adjusted for age and sex and accounted for changes in vitamin D exposure during follow-up. They also used inverse probability of treatment weighting, or IPTW, to create a statistical “pseudo-population” in which the exposed and unexposed groups were more comparable. Propensity scores were calculated from age, sex, white blood cell count, platelet count and hemoglobin level. The researchers then used weighted Cox models, included laboratory measurements as time-varying variables and evaluated potential statistical problems such as multicollinearity and violations of the proportional-hazards assumption. A Mantel–Byar test was applied to address immortal-time bias, which can occur when patients must survive long enough to be classified as exposed.

The apparent survival advantage was notable because the vitamin D users were not, on average, younger or obviously healthier at diagnosis. Their median age was 74.1 years, compared with 71.1 years among nonusers. Despite that difference, the vitamin D group showed a median TFS of 147 months—more than 12 years—while the nonuser group had a median of 82 months, or just under seven years. The statistical association persisted after the investigators attempted to balance measurable differences between the groups. These results represent a validation of earlier work by the same research team, which had linked vitamin D supplementation with longer treatment-free survival and, among younger patients, a longer time to first treatment. The importance of the new analysis lies in its scale and real-world setting: rather than relying on a small clinical experiment or a single laboratory measurement, it follows thousands of patients across routine healthcare records. Even so, the study remains observational. Patients were not randomly assigned to take vitamin D, and the records may not capture every factor that influenced both supplementation and leukemia outcomes.

There are biological reasons why vitamin D might plausibly affect CLL, although the study did not directly test those mechanisms. CLL cells are malignant B lymphocytes, and previous research cited by the investigators has shown that B-CLL cells can express higher levels of the vitamin D receptor than normal B cells. When vitamin D or its active derivatives bind to this receptor, they may influence gene-regulatory pathways involved in cell proliferation, differentiation and survival. Laboratory experiments have reported that pharmacologic vitamin D derivatives can promote apoptosis—the regulated process of cellular self-destruction—through pathways involving caspase 3 and caspase 9. Vitamin D may also influence the tumor microenvironment, the network of immune and support cells surrounding leukemia cells. Deficiency has been proposed to increase the activity of myeloid-derived suppressor cells, immune cells that can dampen antitumor responses and potentially support leukemia growth through regulatory molecules such as microRNA-155. These mechanisms remain hypotheses in the context of patients receiving ordinary supplementation; effects observed with high concentrations of vitamin D derivatives in vitro cannot be assumed to occur at standard clinical doses.

The findings should therefore be interpreted as a signal for further research, not as a recommendation for every person with CLL to begin supplementation. Vitamin D supplements are not risk-free when taken in excessive amounts, and their safety and usefulness depend on a patient’s blood levels, kidney function, calcium balance, medications and other medical conditions. The study also grouped together vitamin D supplements and vitamin D analogs, which may have different biological properties and clinical uses. It did not establish whether supplementation corrected a documented deficiency, whether blood vitamin D concentrations rose consistently, or which dose and formulation might be relevant. In addition, electronic health records can contain incomplete information about adherence, over-the-counter use, diet, sunlight exposure, socioeconomic factors, physical activity and general health. These variables could influence both the likelihood of taking vitamin D and the risk of needing CLL treatment. The fact that vitamin D users were older than nonusers also highlights how complex treatment decisions and health behaviors can be in routine practice, even after statistical adjustment.

The next step is a prospective randomized trial in which people with early-stage CLL are assigned to vitamin D or placebo and followed under standardized conditions. Such a study could determine whether correcting vitamin D deficiency actually slows CLL progression, or whether supplementation merely marks patients who receive different levels of healthcare or have other favorable characteristics. It could also clarify whether the benefit, if real, applies to all patients or only to those with low vitamin D levels, particular genetic features or specific disease-risk profiles. For now, the Israeli cohort offers a striking observation: during a period when physicians have few proven tools to alter the course of early CLL, vitamin D exposure was associated with nearly five additional years of median treatment-free survival. That result is likely to attract attention because it connects a familiar nutritional supplement with one of leukemia’s most important clinical outcomes. But only controlled prospective evidence can determine whether vitamin D is an active ingredient in that association—or simply a marker traveling alongside it.

In a landmark study recently published in Nature Communications, a team of scientists from the University of Chicago has made a seminal breakthrough, elucidating how chronic UV exposure precipitates inflammation at the cellular level and propels the transformation of normal skin cells into malignant ones. Central to their discovery is a protein known as YTHDF2, a molecular gatekeeper whose degradation after UV damage opens the floodgates to harmful inflammation, setting the stage for carcinogenesis.

Skin cancers, including basal cell carcinoma and squamous cell carcinoma, account for over 5.4 million diagnosed cases annually in the United States alone, with over 90% directly linked to excessive UV radiation from sunlight. UV rays inflict DNA damage and provoke oxidative stress within skin cells, igniting inflammatory pathways responsible for the hallmark symptoms of sunburn: redness, blistering, and pain. Despite the ubiquity of these inflammatory responses, the fine-tuned molecular regulation that governs inflammation post-UV exposure has remained elusive—until now.

The investigative team, led by Professor Yu-Ying He, delved into the nuanced interactions between environmental stressors and cellular molecular machinery. Their focus centered on RNA metabolism, a critical nexus where small cellular molecules dictate gene expression and immune responses. RNA, or ribonucleic acid, typically translates genetic blueprints into functional proteins; however, a subset called non-coding RNAs, which do not encode proteins, plays intricate regulatory roles particularly within the cellular compartments of the nucleus and cytoplasm.

Through a series of rigorous experiments and multi-omics analyses, the researchers identified YTHDF2—a protein that selectively recognizes RNA sequences tagged with a chemical modification known as N6-methyladenosine (m6A)—as a pivotal moderator of the inflammatory cascade triggered by UV stress. Under normal conditions, YTHDF2 binds these m6A-marked RNA molecules, orchestrating their metabolism to maintain cellular homeostasis and dampen excessive inflammation. However, UV radiation triggers a notable depletion of YTHDF2 levels in skin cells, unleashing unchecked inflammatory responses.

Further inquiry revealed that YTHDF2 specifically interacts with a distinct non-coding RNA species, U6 small nuclear RNA (snRNA), which is also modified by m6A. U6 snRNA traditionally resides within the nucleus, facilitating RNA splicing and gene regulation. Surprisingly, under UV-induced stress, elevated levels of U6 snRNA translocate to endosomes—membrane-bound cellular compartments conventionally involved in material recycling—a remarkable mislocalization that contributes to pathological signaling.

This translocation is mediated by a protein named SDT2, which escorting U6 snRNA into the endosome, inadvertently drags along YTHDF2. Within the endosomal microenvironment, YTHDF2 exerts a suppressive effect, preventing U6 snRNA from aberrantly activating toll-like receptor 3 (TLR3), an immune sensor that upon stimulation ignites potent inflammatory pathways linked to tumorigenesis. The absence of YTHDF2 following UV exposure removes this inhibitory checkpoint, allowing U6 snRNA to engage TLR3 promiscuously, thereby exacerbating inflammatory damage and fostering a pro-carcinogenic milieu.

The study’s revelations unmask a previously unappreciated surveillance paradigm in cellular immunity and inflammation, positioning YTHDF2 as a crucial sentinel that curbs destructive inflammatory signaling triggered by self-RNA molecules. This intricate interplay between RNA modifications, protein readers, and immune sensors offers fresh mechanistic insights into how environmental insults like UV radiation transmute benign skin cells into malignant counterparts through dysregulated inflammation.

These findings not only augment our molecular understanding of skin cancer pathophysiology but also illuminate promising avenues for therapeutic innovation. By targeting the RNA-protein interactions and trafficking processes that underpin UV-induced inflammatory responses, novel interventions could be designed to bolster YTHDF2 function or mimic its regulatory role, thereby mitigating cancer risk. Such strategies might herald a new era in dermatological oncology, focusing on molecular precision to preemptively quell the inflammatory precursors of skin malignancies.

Moreover, this breakthrough prompts a revision of current paradigms regarding non-coding RNA dynamics and subcellular trafficking, expanding the landscape of RNA biology beyond canonical realms. The discovery that non-coding RNAs like U6 can aberrantly shuttle into endosomes to modulate innate immune receptors challenges long-held notions and invites further exploration into the cross-talk between RNA metabolism and immune regulation in diverse disease states.

Professor Yu-Ying He and colleagues emphasize that while inflammation is indispensable for combating infections and repairing tissue damage, its chronic or dysregulated activation is a double-edged sword that can precipitate oncogenic transformation. Their work deftly elucidates the molecular underpinnings that keep such inflammation in check under physiological conditions, revealing vulnerabilities exploited by UV-induced damage.

The research was supported by prominent institutions including the National Institutes of Health and the University of Chicago Medicine Comprehensive Cancer Center, underscoring the importance and high impact of this work. Collaborative contributions from a multidisciplinary team further highlight the integrative approach necessary to dissect complex cellular mechanisms influencing disease.

Together, these insights forge a vital link between environmental exposures, molecular regulatory systems, and cancer development, providing a blueprint for future research and clinical innovations aimed at safeguarding skin health. As ultraviolet radiation continues to pose a global health challenge, understanding and manipulating the molecular sentinels that guard against its deleterious effects may become key to reducing the burden of skin cancer worldwide.

Subject of Research: Cells
Article Title: YTHDF2 regulates self non-coding RNA metabolism to control inflammation and tumorigenesis
News Publication Date: 12-Nov-2025
Web References: https://www.nature.com/articles/s41467-025-64898-7
References: He, Y.-Y. et al. (2025). YTHDF2 regulates self non-coding RNA metabolism to control inflammation and tumorigenesis. Nature Communications. https://www.nature.com/articles/s41467-025-64898-7
Keywords: Cell biology, Cancer, Skin cancer, Ultraviolet radiation

Fatigue in children has long been a nebulous clinical symptom, usually attributed to psychological stress, infection, or vague systemic illnesses without clear, treatable causes. The new research underscores the importance of systematically evaluating vitamin D levels in children presenting with fatigue, emphasizing that what has been previously considered functional or unexplained tiredness might in fact be a direct consequence of suboptimal vitamin D status. Vitamin D, traditionally recognized for its integral role in calcium homeostasis and skeletal development, is now understood to exert extensive effects on cellular energy metabolism, immune modulation, and muscular function—all key factors in maintaining optimal physical stamina and alertness.

At the molecular level, vitamin D interacts with the vitamin D receptor (VDR), which is expressed not only in bone cells but also in numerous tissues including muscle fibers, neurons, and immune cells. Upon activation, VDR influences the transcription of genes involved in mitochondrial function and oxidative phosphorylation, processes essential for ATP generation and subsequent energy supply. Insufficient vitamin D disrupts these pathways, potentially leading to decreased cellular energy output. The resultant bioenergetic deficit manifests clinically as fatigue, diminished exercise tolerance, and impaired cognitive performance in children.

Moreover, immune dysregulation caused by vitamin D deficiency may indirectly exacerbate fatigue. Vitamin D exerts immunomodulatory effects, curbing excessive pro-inflammatory cytokine production while enhancing anti-inflammatory pathways. Chronic low-grade inflammation, a known contributor to fatigue syndromes, may thus be perpetuated in the setting of vitamin D insufficiency. Devulapalli’s study highlights biochemical markers correlating low vitamin D with elevated inflammatory mediators in fatigued pediatric cohorts, drawing a compelling mechanistic link between nutrient deficiency, immune status, and symptomatology.

Clinically, the study advocates for routine screening of serum 25-hydroxyvitamin D [25(OH)D] concentrations in children who present with unexplained fatigue. The research points out that current pediatric practice often neglects this simple diagnostic step, leading to missed therapeutic opportunities. Intriguingly, the data indicate that correcting vitamin D deficiency through appropriate supplementation results in significant amelioration of fatigue symptoms, thereby dramatically improving the quality of life in affected children. These findings hold particular significance for populations at higher risk of deficiency due to limited sun exposure, dietary inadequacies, or genetic factors affecting vitamin D metabolism.

The epidemiological dimension of the study reveals a startling prevalence of hypovitaminosis D in pediatric populations worldwide, spanning diverse geographic and socio-economic contexts. Despite abundant sunlight in some regions, lifestyle changes such as increased indoor activities, use of sunblock, and urban living contribute to decreased cutaneous synthesis of vitamin D. Consequently, an increasing number of children face the dual burden of fatigue and poor nutritional status, accentuating healthcare disparities in vulnerable groups. This global scope underscores the urgency of public health interventions targeting vitamin D sufficiency.

Importantly, Devulapalli’s research explores the kinetic relationship between vitamin D repletion and symptomatic improvement, providing a pharmacodynamic rationale for supplementation regimens. The study carefully delineates dosing protocols, duration of therapy, and monitoring parameters to optimize clinical outcomes. Attention is paid to the balance between efficacy and safety, with a strong emphasis on avoiding hypervitaminosis D and associated complications. These insights equip clinicians with evidence-based strategies to tackle pediatric fatigue through vitamin D correction.

From a neuroscientific perspective, the presence of VDR in brain tissue suggests that vitamin D may influence neurotransmitter synthesis and neuroplasticity, further explaining cognitive fatigue reported in affected children. Studies cited in the article demonstrate correlations between low vitamin D status and impaired concentration, memory, and mood disturbances, symptoms often accompanying physical fatigue. Integrating neurocognitive assessments into clinical practice could thus enhance diagnostic precision and guide holistic intervention approaches.

The study also critiques existing clinical guidelines that insufficiently address vitamin D’s systemic roles beyond bone health. The author calls for revision of pediatric fatigue management protocols to incorporate vitamin D status evaluation as a standard of care. Such paradigm shifts promise reduction in misdiagnosis and under-treatment, ultimately decreasing healthcare costs linked to unnecessary investigations and therapies.

Technological advances in vitamin D measurement methods are featured as well, with high-performance liquid chromatography and mass spectrometry-based assays offering improved accuracy and reproducibility over conventional immunoassays. Adoption of these techniques facilitates precise detection of deficiency states, advancing clinical research and personalized medicine applications.

Furthermore, the article sheds light on the potential interplay between vitamin D and other micronutrients implicated in energy metabolism, such as iron, magnesium, and B vitamins. While the focus remains on vitamin D, the holistic nutritional status is emphasized as a determinant of fatigue, advocating for comprehensive assessment and multimodal interventions when appropriate.

Environmental, genetic, and lifestyle factors influencing vitamin D levels and fatigue etiology receive detailed scrutiny, highlighting population heterogeneity and the need for individualized therapeutic strategies. This personalized medicine approach envisages integrating genomic, metabolomic, and exposomic data to tailor preventative and corrective measures, minimizing fatigue burden in children.

In closing, the study by Devulapalli C.S. is a seminal contribution drawing critical attention to vitamin D deficiency as a modifiable, often unrecognized cause of fatigue in children. By unraveling complex biochemical and immunological underpinnings, it bridges fundamental research and clinical practice. Its implications extend beyond symptom relief, promising enhanced pediatric health outcomes and proactive nutritional strategies worldwide.

The transformative potential of these findings invites further multidisciplinary research to refine understanding, validate interventions across diverse cohorts, and shape evidence-based pediatric guidelines. In an era increasingly recognizing the importance of early-life nutritional sufficiency, vitamin D emerges as a key agent in restoring vitality and preventing chronic fatigue in younger generations, heralding a paradigm shift in pediatric healthcare.

Subject of Research: Vitamin D deficiency as a contributing factor to fatigue in children.

Article Title: Vitamin D deficiency and fatigue in children: an overlooked but modifiable factor?.

Article References:
Devulapalli, C.S. Vitamin D deficiency and fatigue in children: an overlooked but modifiable factor?. World J Pediatr (2025). https://doi.org/10.1007/s12519-025-00970-y

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s12519-025-00970-y